Publications by authors named "Devra Olson"

Claim this Profile
T
Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical models.
David R Gruber, Elizabeth J Cummins, Weiping Zeng, Michelle Ulrich, Kaleb Smith, Devra J Olson

Mol Cancer Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.
Sherif Abdelhamed, Xinqun Zhang, Weiping Zeng, Bryan Grogan, Luke Schilperoort, Devra J Olson

Mol Cancer Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.
Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred

Cancer Res Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Rebecca Mazahreh, Marsha L Mason, John J Gosink, Devra J Olson, Robert Thurman

Mol Cancer Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis